Japan's Kissei Buys MediciNova Stock To Improve Licensing Deal
This article was originally published in PharmAsia News
Executive Summary
Japan biotech MediciNova plans to issue stock to Kissei Pharmaceutical to help cover the cost of developing asthma and pulmonary drugs it licensed earlier